Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708288 | 0.91 | RAB9A (0.61) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1331780 | 0.89 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL1331055 | 0.89 | RAB9A (0.77) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1329859 | 0.88 | DRD4 (0.57) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7703129 | 0.88 | RAB9A (0.75) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1330392 | 0.88 | RAB9A (0.60) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1331002 | 0.87 | KMT2A (0.63) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1330315 | 0.87 | RAB9A (0.68) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1331493 | 0.87 | NPC1 (0.59) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1329852 | 0.85 | MAPT (0.59) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | claimed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | claimed |
| CN-101784515-A | Pyridinecarboxamide and benzamide derivatives as taar1 ligands | HOFFMANN LA ROCHE | 2010-07-21 | — | — | CN | claimed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | claimed |
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281871-A1 | TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2011-11-17 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008305-B2 | TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| CN-101784515-A | Pyridinecarboxamide and benzamide derivatives as taar1 ligands | HOFFMANN LA ROCHE | 2010-07-21 | — | — | CN | disclosed |
| EP-2185502-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009019149-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019149-A1 | PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036452-A1 | TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036452-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | RAB9A 2200/4885NPC1 1378/4885MAPT 1820/4885 |
| US-20110281871-A1 | TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | RAB9A 2200/4885NPC1 1378/4885MAPT 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.